Pricing methodologies in Medicare vary from one component of the system to another, often leading to conflicting incentives. Failure to recognize linkages may result in inefficient allocation of resources and higher overall costs. To motivate the analysis, I derive pricing rules for a welfare-maximizing regulator. I show that while optimal inpatient payments are standard Ramsey prices, optimal outpatient payments must incorporate net loss due to unnecessary hospitalizations, as well as supply elasticities. Ignoring this leads the myopic regulator to underprovide preventive services. The dialysis program is a useful case for empirical investigation, since payments for maintenance care are more rigidly determined than payments for related hos...
In recent years, drug manufacturers and private payers have expressed interest in novel pricing mode...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
172-179BACKGROUND: Treatment costs of end-stage renal disease with dialysis are high and vary betwee...
Most of the existing medical economics literature is descriptive rather than analytical, summarizing...
It is not profound to say that the American health care enterprise is in a state of flux. Since the ...
To control Medicaid's expenditure on prescription drugs, 1990 legislation established a rebate progr...
This Article will first examine the problem of health care cost inflation and the payment strategies...
Our excess health care spending in the United States is driven largely by our high health care price...
With Medicare’s rising costs threatening the country’s fiscal health, policymakers have focused thei...
The efficiency of publicly-subsidized, privately-provisioned social insurance programs depends on th...
We study physician agency and optimal payment policy in the context of an expensive medication used ...
Abstract. Recently, budget-conscious policymakers have shifted their attention to the physician serv...
We determine the optimal health policy mix when the average utility of patients increases with the s...
This gaper analyzes the welfare implications of fixed price regulation in a model in which consumers...
Abstract We analyse the properties of optimal price adjustment to hospitals when no lump-sum transfe...
In recent years, drug manufacturers and private payers have expressed interest in novel pricing mode...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
172-179BACKGROUND: Treatment costs of end-stage renal disease with dialysis are high and vary betwee...
Most of the existing medical economics literature is descriptive rather than analytical, summarizing...
It is not profound to say that the American health care enterprise is in a state of flux. Since the ...
To control Medicaid's expenditure on prescription drugs, 1990 legislation established a rebate progr...
This Article will first examine the problem of health care cost inflation and the payment strategies...
Our excess health care spending in the United States is driven largely by our high health care price...
With Medicare’s rising costs threatening the country’s fiscal health, policymakers have focused thei...
The efficiency of publicly-subsidized, privately-provisioned social insurance programs depends on th...
We study physician agency and optimal payment policy in the context of an expensive medication used ...
Abstract. Recently, budget-conscious policymakers have shifted their attention to the physician serv...
We determine the optimal health policy mix when the average utility of patients increases with the s...
This gaper analyzes the welfare implications of fixed price regulation in a model in which consumers...
Abstract We analyse the properties of optimal price adjustment to hospitals when no lump-sum transfe...
In recent years, drug manufacturers and private payers have expressed interest in novel pricing mode...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
172-179BACKGROUND: Treatment costs of end-stage renal disease with dialysis are high and vary betwee...